Barry M Bernstein

US Patent:

8466159, Jun 18, 2013

Filed:

Sep 4, 2012

Appl. No.:

13/603022

Inventors:

Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40

US Classification:

51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e. g. , ritonavir), and ribavirin.

US Patent:

8492386, Jul 23, 2013

Filed:

Sep 4, 2012

Appl. No.:

13/603006

Inventors:

Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40
A61K 31/675

US Classification:

51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81

Abstract:

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e. g. , ritonavir).

US Patent:

20130072528, Mar 21, 2013

Filed:

Sep 17, 2012

Appl. No.:

13/621454

Inventors:

Barry M. Bernstein - Mequon WI, US
Scott C. Brun - Green Oaks IL, US

Assignee:

ABBVIE INC. - North Chicago IL

International Classification:

A61K 31/427
A61P 31/14

US Classification:

514365

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering Compound I (or a pharmaceutically acceptable salt thereof) and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free.

US Patent:

20140024613, Jan 23, 2014

Filed:

Jun 26, 2013

Appl. No.:

13/927814

Inventors:

Thomas J. PODSADECKI - Northbrook IL, US
Barry M. BERNSTEIN - Mequon WI, US
Martin S. KING - Lincolnshire IL, US

International Classification:

A61K 31/7068
A61K 31/497
A61K 31/407
A61K 31/427
A61K 31/4025
A61K 45/06
A61K 31/7056
A61K 31/513

US Classification:

514 49, 514 43, 51425505, 514274, 514365, 514422

Abstract:

In one aspect, the present invention features HCV therapies comprising administering to a patient in need thereof an HCV protease inhibitor and ritonavir, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the HCV protease inhibitor. The HCV therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies.

US Patent:

20220288153, Sep 15, 2022

Filed:

Sep 24, 2021

Appl. No.:

17/484287

Inventors:

- North Chicago IL, US
Barry M. Bernstein - Mequon WI, US
Andrew L. Campbell - Lake Forest IL, US
Sandeep Dutta - Lincolnshire IL, US
Chih-Wei Lin - Vernon Hills IL, US
Wei Liu - Mundelein IL, US
Rajeev M. Menon - Buffalo Grove IL, US
Thomas J. Podsadecki - Chicago IL, US
Tianli Wang - Lake Bluff IL, US
Sven Mensing - Mannheim, DE

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 38/06
A61K 31/454
A61K 31/498
A61K 31/7056
A61K 31/7072
A61K 38/05

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

US Patent:

20190336565, Nov 7, 2019

Filed:

May 7, 2019

Appl. No.:

16/405029

Inventors:

- North Chicago IL, US
Barry M. Bernstein - Mequon WI, US
Andrew L. Campbell - Lake Forest IL, US
Sandeep Dutta - Lincolnshire IL, US
Chih-Wei Lin - Vernon Hills IL, US
Wei Liu - Mundelein IL, US
Rajeev M. Menon - Buffalo Grove IL, US
Thomas J. Podsadecki - Chicago IL, US
Tianli Wang - Lake Bluff IL, US
Sven Mensing - Mannheim, DE

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 38/06
A61K 31/498
A61K 31/7072
A61K 38/05
A61K 31/454

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

US Patent:

20180177778, Jun 28, 2018

Filed:

Jun 28, 2016

Appl. No.:

15/738762

Inventors:

- North Chicago IL, US
Tolga Baykal - Libertyville IL, US
Barry M. Bernstein - Mequon WI, US
Scott c. Brun - Green Oaks IL, US
Daniel E. Cohen - Wilmette IL, US
Emily O. Dumas - Libertyville IL, US
Sandeep Dutta - Lincolnshire IL, US
Amit Khatri - Waukegan IL, US
Cheri E. Klein - Northbrook IL, US
Rajeev M. Menon - Buffalo Grove IL, US
Sven Mensing - Ilversheim, DE
Thomas J. Podsadecki - Chicago IL, US
Lino X Rodrigues Jr. - Chicago IL, US
Regis A. Vilchez - Lake Forest IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/497
A61P 31/14
A61K 31/4025
A61K 31/427
A61K 31/7056

Abstract:

The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.

US Patent:

20180177779, Jun 28, 2018

Filed:

Jul 7, 2016

Appl. No.:

15/738773

Inventors:

- North Chicago IL, US
Barry M. Bernstein - Mequon WI, US
Andrew Campbell - Lake Forest IL, US
Sandeep Dutta - Lincolnshire IL, US
Chih-Wei Lin - Vernon Hills IL, US
Wei Liu - Riverwoods IL, US
Rajeev M. Menon - Buffalo Grovee IL, US
Sven Mensing - Ilversheim, DE
Thomas J. Podsadecki - Chicago IL, US
Tianli Wang - Lake Bluff IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/498
A61K 31/454
A61K 31/7072
A61P 31/14

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.